Ingredient comparison

Liraglutide vs Semaglutide

Last updated

Compare the ingredients, then check the specific brand, formulation, and dose. Approved uses and prices vary by product.

Liraglutide vs Semaglutide: lowest prices now

  • Liraglutide: lowest FDA-approved

    Amazon Pharmacy

    $1,230.30 per 5 pens · about $1230 per 30 days

  • Liraglutide: lowest compounded on a monthly plan, not FDA-approved

    Henry Meds

    $179/mo

  • Semaglutide: lowest FDA-approved

    NovoCare (Novo Nordisk)

    $149/30 days · about $149 per 30 days

  • Semaglutide: lowest compounded on a monthly plan, not FDA-approved

    Collective

    $59/mo + $199/yr membership · about $76 a month over a year with the membership · first order: membership free for the first 21 days, never charged if you cancel before

Every cash quote was checked on or after .Data feeds · Nov 16, 2026 UTC
Liraglutide vs Semaglutide: overview
CompareLiraglutideSemaglutide
What it is for

FDA-approved for

  • Weight loss
  • Type 2 diabetes
  • Heart risk

FDA-approved for

  • Weight loss
  • Type 2 diabetes
  • Heart risk
  • Kidney
  • Liver
Brands
Route & frequency

Subcutaneous injection

Once daily

Subcutaneous injection (Ozempic, Wegovy); oral tablet (Rybelsus, oral Ozempic, Wegovy pill)

Once weekly (injectable); once daily (oral)

FDA shortage report
In shortage

National reporting does not confirm stock at your pharmacy.

Coverage & source records

National reporting does not confirm stock at your pharmacy.

Coverage & source records
What was tested together

Direct comparative evidence

No direct comparative trial is included for these ingredients in our reviewed catalog. The separate trial results below do not establish which works better.

Product-specific self-pay

What the quoted price covers

Lowest tracked quotes for FDA-approved products, selected separately for each price basis. Entry prices may refer to different brands or formulations. Supply periods, eligibility, refill deadlines, and additional fees can change what you pay.

Liraglutide vs Semaglutide: sourced cash quotes
CompareLiraglutideSemaglutide
Advertised entry price
from $349/mo (healifynow.com/saxenda)

Saxenda via HealifyNow

HealifyNow

its Saxenda page says "From $349/month" for Saxenda (liraglutide 3 mg, weight management), and "Your first consultation is free. No insurance needed, and you only pay if you start treatment." On the same page, "Can I cancel my Saxenda plan at any time?" is answered "Yes. There are no contracts, and you can cancel from your patient portal."

Billed per month; days of supply not on record, so ordered as four weekly doses.

Checked on healifynow.com

Price conditions

its Saxenda page says "From $349/month" for Saxenda (liraglutide 3 mg, weight management), and "Your first consultation is free. No insurance needed, and you only pay if you start treatment." On the same page, "Can I cancel my Saxenda plan at any time?" is answered "Yes. There are no contracts, and you can cancel from your patient portal."

A starting price: the page does not say what the figure includes or how it changes with the dose; the page prices it per month with no contracts. Its pages also list "Liraglutide From $149/mo" without saying which kind of liraglutide it is. FDA-approved product.

$149/30 days (pharmacy.amazon.com/Novo-Nordisk-Inc-WEGOVY-1-5-MG-TABLET-Bottle-30-Tablet/dp/B0GD6568YL)

Wegovy pill via Amazon Pharmacy

Amazon Pharmacy

without insurance, 1.5 mg; includes the manufacturer coupon if eligible (list price $1,348.80); prescription required

30-day supply (pharmacy.amazon.com)

$149 per 30 days at this quoted rate

Checked on pharmacy.amazon.com

Price conditions

without insurance, 1.5 mg; includes the manufacturer coupon if eligible (list price $1,348.80); prescription required

Amazon fills a prescription you already have and delivers in all 50 states. FDA-approved product.

30-day supply

At the named trial dose
~$372/mo (goodrx.com/liraglutide-saxenda)

Generic liraglutide 3 mg pens (Saxenda generic), GoodRx coupon

At 3 mg

GoodRx

Published price at 3 mg

Third-party reported price

30-day supply (dailymed.nlm.nih.gov)

$372.45 per 30 days at this quoted rate

Checked on goodrx.com

Price conditions

Published price at 3 mg

GoodRx lists this liraglutide (Saxenda) only as a generic; its price is for one carton of five 18 mg/3 mL pens. Prices vary by pharmacy.

Five pens hold 90 mg: 30 days at the 3 mg daily dose.

30-day supply

$349/28 days (pharmacy.amazon.com/Novo-Nordisk-WEGOVY-2-4-MG-0-75-ML-PEN-INJECTOR-Box-3-Milliliter/dp/B09BHXXL2R)

Wegovy pen via Amazon Pharmacy

At 2.4 mg

Amazon Pharmacy

without insurance, 2.4 mg; includes the manufacturer coupon if eligible (list price $1,349.01)

28-day supply (pharmacy.amazon.com)

≈ $373.93 per 30 days at this quoted rate

Checked on pharmacy.amazon.com

Price conditions

without insurance, 2.4 mg; includes the manufacturer coupon if eligible (list price $1,349.01)

Amazon fills a prescription you already have and delivers in all 50 states. Its $199 for 0.25 mg "Includes $100.00 off with manufacturer coupon if eligible": Novo Nordisk's coupon, which its terms limit to a new patient's first two 28-day fills, filled by Dec 31, 2026. FDA-approved product.

28-day supply

Every offerAll 29 offersAll 952 offers

USD self-pay, not insurance or pharmacy acquisition cost. A trial dose is not a personal dosing recommendation. Compounded offers are shown separately in the offer browser and are not FDA-approved.

Separate studies

Trial outcomes in context

Each result belongs to its own trial, population, dose, and analysis. Weight loss, HbA1c change, and adverse events may come from different studies even within one ingredient. These are study averages, not predictions of your result.

Liraglutide vs Semaglutide: individual trial outcomes
CompareLiraglutideSemaglutide
Weight change
−8% (nejm.org/doi/full/10.1056/NEJMoa1411892) (-8.0% at 56 wks · SCALE Obesity · 3.0 mg daily (Saxenda))

-8.0% at 56 wks

SCALE Obesity (nejm.org)

3.0 mg daily (Saxenda)

Analysis not classified; see trial methods

−14.9% (nejm.org/doi/full/10.1056/NEJMoa2032183) (-14.9% at 68 wks · STEP 1 · 2.4 mg weekly (Wegovy))

-14.9% at 68 wks

STEP 1 (nejm.org)

2.4 mg weekly (Wegovy)

Accounts for treatment discontinuation

Study context

The headline is the standard 2.4 mg maintenance dose (Wegovy), the dose used in STEP 1 and one of the permitted doses in SURMOUNT-5. Other doses and formulations have their own trials, including STEP UP and OASIS 4. Their results are not interchangeable.

HbA1c change (percentage points)
−1.3 pp (doi.org/10.1001/jama.2015.9676) (-1.3% at 56 wks · SCALE Diabetes · HbA1c change in percentage points)

-1.3 percentage points at 56 wks

SCALE Diabetes (doi.org)
−1.6 pp (thelancet.com/journals/lancet/article/PIIS0140-6736(21)00213-0/abstract) (-1.6% at 68 wks · STEP 2 · HbA1c change in percentage points)

-1.6 percentage points at 68 wks

STEP 2 (thelancet.com)
Adverse events

Stopped treatment for adverse events

9.8% (accessdata.fda.gov/drugsatfda_docs/label/2014/206321orig1s000lbl.pdf) (9.8% vs 4.3% placebo (3.0 mg) · FDA Saxenda label, pooled 3.0 mg obesity trials (SCALE))

Reported nausea

39.3% (accessdata.fda.gov/drugsatfda_docs/label/2014/206321orig1s000lbl.pdf) (Nausea in the drug arm · FDA Saxenda label, pooled 3.0 mg obesity trials (SCALE))

FDA Saxenda label, pooled 3.0 mg obesity trials (SCALE)

from the FDA Saxenda adverse-reactions table (the SCALE Obesity trial paper is paywalled); essentially identical to the trial's own ~9.9% / ~40% figures

Stopped treatment for adverse events

7% (nejm.org/doi/full/10.1056/NEJMoa2032183) (7.0% vs 3.1% placebo · STEP 1 (2.4 mg, 68 wks, obesity))

Reported nausea

44.2% (nejm.org/doi/full/10.1056/NEJMoa2032183) (Nausea in the drug arm · STEP 1 (2.4 mg, 68 wks, obesity))

STEP 1 (2.4 mg, 68 wks, obesity)

From FDA and CMS records

Timing, generics and coverage

Read from each FDA label, FDA's Orange Book and CMS's Part D files, and updated when they change.

BrandSoonest top doseHalf-lifeGeneric approved?Patent on the medicine toOn Medicare Part D, 2025
Ozempic2 mg from week 13about 1 weekNot yet: tentative onlyDec 5, 20312,044,798
Wegovy7.2 mg from week 21about 1 weekNoDec 5, 2031108,843
Rybelsus14 mg from day 61about one weekNoMay 2, 2034280,455
Victoza1.8 mg from week 3about 13 hoursYes, 8None listed6,810
Saxenda3 mg from week 5about 13 hoursYes, 3None listedNone listed

How long each takes · Generics and patents · Who covers what

Check the product label

Approved uses & full records

Liraglutide

Indications depend on the brand and formulation. Read the product-specific indications and prescribing information in the full record.

522 registered ingredient studies (clinicaltrials.gov/search). Count checked . Research activity, not a measure of evidence quality.

Open full record

Semaglutide

Indications depend on the brand and formulation. Read the product-specific indications and prescribing information in the full record.

806 registered ingredient studies (clinicaltrials.gov/search). Count checked . Research activity, not a measure of evidence quality.

Open full record
Reading the comparison

Common questions

Is Liraglutide or Semaglutide better for weight loss?

No trial on our list compared them directly. In separate trials: Liraglutide -8.0% at 56 wks in SCALE Obesity (3.0 mg daily (Saxenda)) (nejm.org); Semaglutide -14.9% at 68 wks in STEP 1 (2.4 mg weekly (Wegovy)) (nejm.org). Separate trials enrolled different people for different lengths of time, so these figures cannot rank them.

Is Liraglutide or Semaglutide safer?

We know of no trial set up to answer that. Stopping because of side effects, each in its own trial and not a head-to-head figure: Liraglutide 9.8% vs 4.3% placebo (3.0 mg) (FDA Saxenda label, pooled 3.0 mg obesity trials (SCALE)) (accessdata.fda.gov); Semaglutide 7.0% vs 3.1% placebo (STEP 1 (2.4 mg, 68 wks, obesity)) (nejm.org). Each FDA label lists its own warnings, and which ones matter depends on your health.

What Semaglutide dose is equivalent to Liraglutide?

No FDA label sets a dose of Liraglutide that equals a dose of Semaglutide, and we know of no trial that defines one. Switching is a prescriber's decision, and each label sets its own starting dose and steps.

Which costs less: Liraglutide or Semaglutide?

Compare the named products and price conditions below. A tracked entry quote can be a different brand or formulation from the product studied in a trial. A trial-dose quote applies only to the named product and dose; neither figure is an estimate of your whole treatment cost or an insurance quote.

Do these trial results tell me which medication is best?

Direct trials compare the treatments, doses, and participants they studied. Results from separate trials differ in population, duration, dose, and analysis, so their percentages do not establish a treatment ranking. Discuss your medical history and the specific product label with a licensed clinician.

Does FDA shortage status mean my pharmacy has stock?

No. FDA shortage records describe national supply reports and covered presentations, not inventory at an individual pharmacy. Unknown status means the data cannot establish a current assessment. Confirm local stock with your pharmacy.

Updated automatically

What changed for Liraglutide and Semaglutide

  • PriceCorrected: Telezen MD, Compounded semaglutide via Telezen MD, $128/mo on its own page (we had from $89/mo) (read on telezenmd.com)
  • PriceCorrected: Ascend Vitality, Compounded semaglutide via Ascend Vitality, $149/mo on its own page (we had from $89/mo) (read on av-life.com)
  • PriceNexLife: Microdose semaglutide via NexLife now $109/mo (was $129/mo) (read on nexlife.com)
  • PriceRow Telehealth: Compounded semaglutide dissolving tablets (ODT) via Row Telehealth now $139/mo (was from $139/mo) (read on rowtelehealth.com)
  • PriceRow Telehealth: Compounded semaglutide via Row Telehealth now $129/mo (was from $129/mo) (read on rowtelehealth.com)
  • TrialResults posted for a Liraglutide study: SCALE KIDS: Research Study to Look at How Well a New Medicine is at Lowering Weight in Children With Obesity (clinicaltrials.gov/study/NCT04775082)

Written from each source's own record as it changes. Every change on GLPcompare

Automated feed checks do not constitute a clinical or editorial review. Sources & methodology

GLPcompare is an informational data platform, not a medical provider or pharmacy. Nothing here is medical advice, a diagnosis, or a recommendation to start, stop, or change any treatment. Data is aggregated from public sources and can be incomplete or out of date. Always confirm with a licensed clinician and the current FDA label.